Results: 4

1.
Figure 2

Figure 2. Overall Survival. From: Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer.

Panel A shows overall survival according to treatment group. Panel B shows the hazard ratios for overall survival in the experimental groups as compared with the group receiving standard treatment (paclitaxel every 3 weeks).

Joseph A. Sparano, et al. N Engl J Med. ;358(16):1663-1671.
2.
Figure 1

Figure 1. Disease-free Survival. From: Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer.

Panel A shows disease-free survival according to treatment group. Panel B shows the hazard ratios for disease-free survival in the experimental groups as compared with the group receiving standard treatment (paclitaxel every 3 weeks).

Joseph A. Sparano, et al. N Engl J Med. ;358(16):1663-1671.
3.
Figure 4

Figure 4. Exploratory Analysis of Disease-free and Overall Survival According to Expression of Hormone Receptors (HR). From: Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer.

The figure shows the hazard ratios for disease-free and overall survival the group receiving weekly paclitaxel in as compared with the group receiving paclitaxel every 3 weeks among patients with HER2-negative disease according to whether the disease was positive or negative for hormone receptors.

Joseph A. Sparano, et al. N Engl J Med. ;358(16):1663-1671.
4.
Figure 3

Figure 3. Exploratory Analysis of Disease-free and Overall Survival According to Expression of Human Epidermal Growth Factor Receptor Type 2 (HER2). From: Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer.

Panel A shows the hazard ratios for disease-free survival and Panel B shows the hazard ratios for overall survival according to HER2 expression in the experimental groups as compared with the group receiving paclitaxel every 3 weeks.

Joseph A. Sparano, et al. N Engl J Med. ;358(16):1663-1671.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk